Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate

Neuroscience

Volumn 100, Issue 1, 2000, Pages 1-9

  Jardemark, K E ^a   Liang, X ^a   Arvanov, V ^a   Wang, R Y ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Antipsychotic drugs; Clozapine; Medial prefrontal cortex; NMDA receptor; Olanzapine; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ELECTROPHYSIOLOGY; INTRACELLULAR RECORDING; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SCHIZOPHRENIA;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG SYNERGISM; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; HALOPERIDOL; MALE; N-METHYLASPARTATE; PIRENZEPINE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VEHICLES;

EID: 0034618815     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00253-0     Document Type: Article

References (77)

1. Alessandri B., Battig K, Welzl H. Effects of ketamine on tunnel maze and water maze performance in the rat. Behav. neural. Biol. 52:1989;194-212.
2. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiat. 135:1978;1081-1084.
3. Arnold S.E. The medial temporal lobe in schizophrenia. J. Neuropsychiat. 9:1997;460-470.
4. Arvanov V.L., Wang R.Y. NMDA-evoked response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res. 768:1997;361-364.
5. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology. 18:1998;197-209.
6. Arvanov V.L., Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of NMDA receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmac. exp. Ther. 289:1999;1000-1006.
7. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate NMDA- and non-NMDA receptor mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmac. exp. Ther. 283:1997;226-234.
8. 2A receptor agonist DOB on NMDA-evoked responses in pyramidal neurons of the rat medial prefrontal cortex. Eur. J. Neurosci. 11:1999;2917-2934.
9. 2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur. J. Neurosci. 11:1999;3064-3072.
10. Bakshi V.P., Serdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmac. exp. Ther. 271:1994;787-794.
11. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. and The Olanzapine HGAD Study Group. (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial, Neuropsychopharmacology 14, 111-123.
12. Boyce S., Rupniak N.M.J., Stevenson M.J., Cook G., Iversen S.D. Psychomotor activity an cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav. Brain. Res. 42:1991;115-121.
13. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends pharmac. Sci. 13:1990;272-276.
14. Cauli B., Audinat E., Lambolez B., Angulo M.C., Ropert N., Tsuzuki K., Hestrin S., Rossier J. Molecular and physiological diversity of cortical nonpyramidal cells. J. Neurosci. 17:1997;3894-3906.
15. Cebers G., Cebere A., Wagner A., Liljequist S. Prolonged inhibition of glutamate reiptake down-regulates NMDA receptor functions in cultured cerebellar granule cells. J. Neurochem. 72:1999;2181-2190.
16. Connors B.W., Gutnick M.J. Intrinsic firing patterns of diverse neocortical neurons. Trends Neurosci. 13:1990;99-104.
17. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
18. Danysz W., Wroblewski J.T., Costa E. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology. 27:1988;653-656.
19. Deutsch S.I., Mastrpaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A glutamatergic hypothesis of schizophrenia: rationale for pharmacology with glycine. Clin. Neuropharmac. 12:1989;1-13.
20. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
21. Finkel A. S. and Redman S. J. (1985) Optimal voltage clamping with single microelectrodes. In Voltage and Patch Clamping with Microelectrodes (eds Smith T. G., Lecar A., Redman S. J. and Gage P. W.). Williams & Wilkins, Baltimore, MD.
22. Giardino L., Bortolotti F., Orazzo C., Pozza M., Monteleone P., Calza L., Maj M. Effect of chronic clozapine administration on 3H-MK-801-binding sites in the rat brain: a side-preference action in cortical areas. Brain. Res. 762:1997;216-218.
23. Gold J.M., Weinberger D.R. Cognitive deficits and the neurobiology of schizophrenia. Curr. Opin. Neurobiol. 5:1995;225-230.
24. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 23:1997;437-458.
25. Halliwell J.V., Adams P.R. Voltage-clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res. 250:1982;71-92.
26. Hanania T., Hillman G.R., Johnson K.M. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Synapse. 31:1999;229-239.
27. Harrison P.J. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 122:1999;593-624.
28. Hertzman M., Reba R.C., Kotlyarove E.V. Single photon emission computerized tomography in phencyclidine and related drug abuse. Am. J. Psychiat. 147:1990;255-256.
29. Holmes K., Keele B., Arvanov V., Shinnick-Gallagher P. Metabotropic glutamate receptor agonist-induced hyperpolarization in rat basolateral amygdala neurons: receptor characterization, second messengers and ion channels. J. Neurophysiol. 76:1996;3059-3069.
30. Ingvar D.H., Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet. ii:1974;1484-1486.
31. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 148:1991;1301-1308.
32. Jentsch J.D., Elsworth J.D., Redmond D.E. Jr, Roth R.H. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J. Neurosci. 17:1997;1769-1775.
33. Jentsch J.D., Redmond D.E. Jr, Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
34. Kawaguchi Y., Kubota Y. Physiological and morphological identification of somatostatin- or vasoactive intestinal polypeptide-containing cells among GABAergic cell subtypes in rat frontal cortex. J. Neurosci. 16:1996;2701-2715.
35. 2A antagonist with a favorable CNS safety profile. J. Pharmac. exp. Ther. 277:1996;968-981.
36. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
37. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr, Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. gen. Psychiat. 51:1994;199-214.
38. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872.
39. Lee M.A., Jayathilaka K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37:1999;1-11.
40. Liang X., Wang R.Y. Biphasic modulatory action of the selective sigma receptor ligand SR31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. Brain Res. 807:1998;208-213.
41. Madison D.V., Lancaster B., Nicoll R.A. Voltage clamp analysis of cholinergic action in the hippocampus. J. Neurosci. 7:1987;733-741.
42. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiat. 42:1997;664-668.
43. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
44. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
45. McCormick D.A., Connors B.W., Lighthall J.W., Prince D.A. Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J. Neurophysiol. 54:1985;782-806.
46. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 213:1996;137-141.
47. Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur. J. Pharmac. 368:1999;1-7.
48. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiat. 52:1995;998-1007.
49. Ossowska K., Pietraszek M., Wardas J., Nowak G., Wolfarth S. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmiedebergs. Arch. Pharmac. 359:1999;280-287.
50. Oster Y., Schramm M. Down-regulation of NMDA receptor activity by NMDA. Neurosci. Lett. 163:1993;85-88.
51. Poncelet M., Santucci V., Paul R., Gueudet C., Lavastre S., Guitard J., Steinberg R., Terranova J.P., Breliere J.C., Soubrie P., Le Fur G. Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology. 32:1993;605-615.
52. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr. Bull. 35:1999;551-560.
53. Rainnie D.G., Holmes K.H, Shinnick-Gallagher P. Activation of postsynaptic metabotropic glutamate receptors by trans-ACPD hyperpolarizes neurons of the basolateral amygdala. J. Neurosci. 14:1994;7208-7220.
54. Riva M.A., Tascedda F., Lovati E., Racagni G. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain. Res. Molec. Brain Res. 50:1997;136-142.
55. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
56. Schweitzer P., Madamba S., Champagnat J., Siggins G.R. Somatostatin inhibition of hippocampal CA1 pyramidal neurons: mediation by arachidonic acid and its metabolites. J. Neurosci. 13:1993;2033-2049.
57. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 14:1996;97-104.
58. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12:1998;21-36.
59. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmac., Berl. 128:1996;371-379.
60. Tollefson G.D., Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiat. 154:1997;466-474.
61. Tsai G., Pinchen Y., Chung L.C., Lange N., Coyle J.T. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiat. 44:1998;1081-1089.
62. Van den Pol A.N., Obietan K., Belousov A. Glutamate hyperexcitability and seizure-like activity throughout the brain and spinal cord upon relief from chronic glutamate receptor blockade in culture. Neuroscience. 74:1996;653-674.
63. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16:1996;373-379.
64. Wachtel H., Turski L. Glutamate: a new target in schizophrenia. Trends pharmac. Sci. 11:1990;219-220.
65. Wang C., Showalter V.M., Hillman G.R., Johnson K.M. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J. Neurosci. Res. 55:1999;762-769.
66. 2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Brain Res. 779:1998;309-313.
67. Wang R.Y., Arvanov V.L., Liang X. Modulation of NMDA- and AMPA- responses in pyramidal neurons of the rat medial prefrontal cortex by chronic treatment with haloperidol or clozapine. Neurosci. Abstr. 24:1998;1827.
68. Wang R.Y., Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology. 19:1998;74-85.
69. Wang R.Y., Liang X., Jardemark K.E. and Arvanov V. (1999) Facilitation of NMDA transmission by olanzapine. In Olanzapine (Zyprexa) - A Novel Antipsychotic (eds P. V. Tran, F. Bymaster, N. Tye, J. Herrera, A. Breier, and G. Tollefson). Williams & Wilkins (in press).
70. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Phil. Trans. R. Soc. Lond. B. 351:1996;1495-1503.
71. Weinberger D.R., Berman K.F., Illowsky B.P. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. gen. Psychiat. 45:1988;609-615.
72. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. gen. Psychiat. 43:1986;114-125.
73. White F.J., Wang R.Y. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons. Life Sci. 32:1983;983-993.
74. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
75. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Jpn J. Psychopharmac. 11:1991;47-48.
76. Yang C.R., Seamans J.K., Gorelova N. Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J. Neurosci. 16:1996;1904-1921.
77. Zheng F., Gallagher J.P. Pharmacologically distinct, pertussis toxin-resistant inward currents evoked by metabotropic glutamate receptor (mGluR) agonist in dorsolateral septal nucleus (DLSN) neurons. J. Neurosci. 15:1995;504-510.